Portland State University

PDXScholar
OHSU-PSU School of Public Health Faculty
Publications and Presentations

OHSU-PSU School of Public Health

3-2020

Screening for Hepatitis C Virus Infection in
Adolescents and Adults: Updated Evidence Report
and Systematic Review for the US Preventive
Services Task Force
Roger Chou
Oregon Health & Science University

Tracy Dana
Oregon Health & Science University

Rongwei Fu
Oregon Health & Science University

Bernadette Zahker
Oregon Health & Science University

Jesse Wagner
Portland State University
Follow this and additional works at: https://pdxscholar.library.pdx.edu/sph_facpub
Part of the Infectious Disease Commons, and the Virus Diseases Commons
See next page for additional authors

Let us know how access to this document benefits you.
Citation Details
Chou, R., Dana, T., Fu, R., Zakher, B., Wagner, J., Ramirez, S., ... & Jou, J. H. (2020). Screening for hepatitis C
virus infection in adolescents and adults: updated evidence report and systematic review for the US
Preventive Services Task Force. Jama, 323(10), 976-991.

This Article is brought to you for free and open access. It has been accepted for inclusion in OHSU-PSU School of
Public Health Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact
us if we can make this document more accessible: pdxscholar@pdx.edu.

Authors
Roger Chou, Tracy Dana, Rongwei Fu, Bernadette Zahker, Jesse Wagner, Shaun Ramirez, Sara Grusing, and
Janice H. Jou

This article is available at PDXScholar: https://pdxscholar.library.pdx.edu/sph_facpub/347

Clinical Review & Education

JAMA | US Preventive Services Task Force | EVIDENCE REPORT

Screening for Hepatitis C Virus Infection in Adolescents and Adults
Updated Evidence Report and Systematic Review
for the US Preventive Services Task Force
Roger Chou, MD; Tracy Dana, MLS; Rongwei Fu, PhD; Bernadette Zakher, MBBS, MPH; Jesse Wagner, MA;
Shaun Ramirez, MPH; Sara Grusing, BA; Janice H. Jou, MD, MHS
Editorial page 936
IMPORTANCE A 2013 review for the US Preventive Services Task Force (USPSTF) of hepatitis C
virus (HCV) screening found interferon-based antiviral therapy associated with increased
likelihood of sustained virologic response (SVR) and an association between achieving an SVR
and improved clinical outcomes. New direct-acting antiviral (DAA) regimens are available.
OBJECTIVE To update the 2013 review on HCV screening to inform the USPSTF.
DATA SOURCES Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the
Cochrane Database of Systematic Reviews through February 2019, with surveillance through
September 2019.
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STUDY SELECTION Randomized clinical trials (RCTs) and nonrandomized treatment studies of

HCV screening and DAA therapy; cohort studies on screening, antiviral therapy, and the
association between an SVR after antiviral therapy and clinical outcomes.
DATA EXTRACTION AND SYNTHESIS One investigator abstracted data; a second checked
accuracy. Two investigators independently rated study quality.
MAIN OUTCOMES AND MEASURES Mortality, morbidity, quality of life, screening and treatment
harms, and screening diagnostic yield.
RESULTS Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other
treatment studies, and 33 cohort studies, with a total of 179 230 participants, were included.
No study evaluated effects of HCV screening vs no screening. One new study since the 2013
review (n = 5917) found similar diagnostic yield of risk-based screening (sensitivity, 82%;
number needed to screen to identify 1 HCV case, 15) and birth cohort screening (sensitivity,
76%; number needed to screen, 29), assuming perfect implementation. Ten open-label
studies (n = 3292) reported small improvements in some quality-of-life and functional
outcomes (eg, less than 3 points on the 0 to 100 36-Item Short Form Health Survey physical
and mental component summary scales) after DAA treatment compared with before
treatment. Two cohort studies (n = 24 686) found inconsistent associations of antiviral
therapy vs no therapy with risk of hepatocellular carcinoma. Forty-nine treatment studies
(n = 10 181) found DAA regimens associated with pooled SVR rates greater than 95% across
genotypes, and low short-term rates of serious adverse events (1.9%) and withdrawal due to
adverse events (0.4%). An SVR after antiviral therapy was associated with decreased
adjusted risk of all-cause mortality (13 studies, n = 36 986; pooled hazard ratio [HR], 0.40
[95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29
[95% CI, 0.23 to 0.38]) vs no SVR.
CONCLUSIONS AND RELEVANCE Direct evidence on the effects of HCV screening on clinical
outcomes remains unavailable, but DAA regimens were associated with SVR rates greater
than 95% and few short-term harms relative to older antiviral therapies. An SVR after antiviral
therapy was associated with improved clinical outcomes compared with no SVR.
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t has been estimated that from 2013 to 2016 approximately
4.1 million people in the US were hepatitis C virus (HCV)
antibody–positive, indicating past exposure, and that of
these, approximately 2.4 million had active infection.1 Persons
born between 1945 and 1965 were estimated to account for
approximately three-fourths of HCV infections. However, recent
increases in acute HCV incidence have mostly affected young persons who inject drugs.2,3
In 2013, the US Preventive Services Task Force (USPSTF) recommended HCV screening for adults born between 1945 and 1965
(“birth cohort” screening) and those at high risk of infection (B
recommendation).4 The recommendation was based on the effectiveness of then-current antiviral therapies with interferon. HCV
treatment has subsequently evolved to direct-acting antiviral (DAA)
regimens without interferon.
This evidence report was conducted to update the 2013 USPSTF review on HCV screening in adults5,6 and a comparative effectiveness review on antiviral treatments,7,8 to inform the USPSTF for
an updated recommendation statement. This report focused on currently recommended DAA regimens and was expanded to include
adolescents.

I

currently recommended DAA regimens vs placebo or an outdated
antiviral regimen10 were included. Because of few randomized
trials of DAA therapy vs placebo or an outdated antiviral regimen,
nonrandomized clinical research treatment studies of DAA
therapy (including those with a single group) and randomized
trials that compared different DAA regimens were also included.
The latter were classified as nonrandomized treatment studies
rather than randomized trials in this review because data from relevant DAA regimens were analyzed separately (ie, the randomized comparison was not used). Cohort studies that controlled for
potential confounders were included for screening; for associations of antiviral therapy (including older regimens) with mortality, hepatocellular carcinoma, and cirrhosis; and for the association between SVR after antiviral therapy and clinical outcomes.
Outcomes were mortality, morbidity (eg, cirrhosis, hepatic
decompensation, liver transplant, extrahepatic manifestations of
HCV infection), quality of life, HCV transmission, sustained virologic response (SVR), harms, and screening yield (sensitivity and
number of new diagnoses per test performed). Studies that
focused on persons co-infected with HIV or hepatitis B virus,
patients receiving transplants, and persons with advanced kidney
disease were excluded.

Methods

Data Abstraction and Quality Rating

Detailed methods and evidence tables with additional study
details are available in the full evidence report at https://
www.uspreventiveservicestaskforce.org /Page/Document/
UpdateSummaryFinal/hepatitis-c-screening1. Figure 1 shows the
analytic framework and key questions (KQs) that guided the
review. KQs on prenatal HCV screening (KQ 1b) and interventions
to prevent vertical HCV transmission during labor and delivery
(KQ5) are addressed in the full report.

One investigator abstracted details about the study design,
patient population, setting, interventions, analysis, followup, and results from each study. A second investigator reviewed
abstracted data for accuracy. Two independent investigators
assessed the quality of each study as good, fair, or poor using predefined criteria developed by the USPSTF (eMethods 2 in the
Supplement).7 Discrepancies were resolved through a consensus
process. In accordance with the USPSTF Procedure Manual, 7
studies rated poor quality because of critical methodological
limitations were excluded.

Data Sources and Searches

Data Synthesis

Ovid MEDLINE, the Cochrane Central Register of Controlled
Trials, and the Cochrane Database of Systematic Reviews were
searched from 2013 through February 2019 (eMethods 1 in the
Supplement). Searches were supplemented by reference list
review of relevant systematic reviews; studies from the prior
USPSTF review6,9 meeting inclusion criteria were carried forward.
Ongoing surveillance was conducted to identify major
studies published since February 2019 that may affect the
conclusions or understanding of the evidence and the related
USPSTF recommendation. The last surveillance was conducted
on September 20, 2019, and identified no studies affecting
review conclusions.

Random effects meta-analysis was performed to summarize the
proportion of patients experiencing SVR and adverse events using
a generalized linear mixed-effects model with a logit link. Analyses
were stratified according to DAA regimen. For SVR, separate
analyses were performed for each HCV genotype. A randomeffects (linear mixed-effects) meta-analysis was also performed on
adjusted hazard ratios (HRs) for SVR after antiviral therapy vs no
SVR and for clinical outcomes (mortality, liver-related mortality,
cirrhosis, and hepatocellular carcinoma). If necessary, the adjusted
HR for SVR vs no SVR was calculated from the adjusted HRs for
SVR and no SVR vs no treatment. Statistical heterogeneity was
assessed using the I2 statistic.11
Subgroup analyses were conducted on geographic setting
(US or Europe; multinational; other), fibrosis stage (cirrhosis
excluded or some patients [up to 20%] with cirrhosis), prior
treatment status (naive or experienced to interferon-based therapies, boceprevir, or telaprevir), quality, and for cohort studies, full
adjustment for key confounding variables (age, sex, fibrosis stage,
and genotype). Stratified analyses were assessed for interactions
using a test for heterogeneity across subgroups. For the association between DAA therapy and SVR rates, sensitivity analysis was
performed by excluding studies in which ribavirin or dasabuvir

Scope of the Review

Study Selection
Two investigators independently reviewed titles, abstracts, and
full-text articles using predefined eligibility criteria. The population for screening was asymptomatic adults and adolescents
without prior HCV infection. For treatment, to evaluate patients
more likely to be asymptomatic and identified by screening, inclusion was restricted to studies in which 20% or less of patients had
cirrhosis at baseline (ⱕ30% for cohort studies that controlled for
fibrosis stage). Randomized clinical trials (RCTs) of screening and
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Figure 1. Analytic Framework: Screening for Hepatitis C Virus Infection in Adolescents and Adults
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Key questions
1

a. Does screening for hepatitis C virus (HCV) infection in pregnant and nonpregnant adolescents and adults without known abnormal
liver enzyme levels reduce HCV-related mortality and morbidity or affect quality of life?
b. Does prenatal screening for HCV infection reduce risk of vertical transmission of HCV infection?d

2

What is the effectiveness of different risk- or prevalence-based methods for screening for HCV infection on clinical outcomes?

3

What is the yield (number of new diagnoses per tests performed) of 1-time vs repeat screening or alternative screening strategies
for HCV infection, and how does the screening yield vary in different risk groups?

4

What are the harms of screening for HCV infection (eg, anxiety and labeling)?

5

What are the effects of interventions during labor and delivery or the perinatal period on risk of vertical transmission of HCV infection?d

6

What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?

7

What is the effectiveness of currently recommended antiviral treatments in achieving a sustained virologic response in patients
with HCV infection?

8

What are the harms of currently recommended antiviral treatments?

9

What is the association between experiencing sustained virologic response following antiviral treatment and reduction in risk
of HCV-related adverse health outcomes?

Evidence reviews for the US Preventive Services Task Force (USPSTF)
use an analytic framework to visually display the key questions that the
review will address to allow the USPSTF to evaluate the effectiveness
and safety of a preventive service. The questions are depicted by linkages
that relate interventions and outcomes. A dashed line indicates a health
outcome that immediately follows an intermediate outcome. See USPSTF
Procedure Manual.7 HCV indicates hepatitis C virus; SVR, sustained
virologic response.
a

Includes persons without abnormal laboratory values. Adolescents are defined

was not used as recommended. For the association between SVR
vs no SVR after antiviral therapy and clinical outcomes, sensitivity
analysis was performed by excluding cohort studies with potentially overlapping populations to ensure that results were not sensitive to double counting of patients. For analyses of harms, trials
978

as those aged 12 to 17 years. Excludes persons living with HIV, transplant
recipients, and patients with renal failure.
b

Defined as HCV antibody testing with confirmatory HCV RNA testing as
indicated.

c

Includes interventions that may affect vertical transmission of HCV, such as
cesarean delivery, amniocentesis, fetal monitoring, management of ruptured
membranes, breastfeeding, and antiviral treatment.

d

Addressed in the full evidence report.

of ribavirin-containing regimens were excluded except for
ombitasvir/paritaprevir/ritonavir/dasabuvir, which is recommended for genotype 1b infection.
Meta-analyses were conducted using SAS version 9.4 (SAS Institute Inc) and RevMan version 5.3.5 (Nordic Cochrane Centre), and
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forest plots were created using Stata/SE version 14.0 (StataCorp).
All significance testing was 2-tailed; P < .05 was considered statistically significant.

Results
Across all KQs addressed in this article, 8 (n = 3397) RCTs (in 6
publications),12-17 48 (n = 7132) nonrandomized treatment studies (in 45 publications),18-62 33 (n = 168 701) cohort studies,63-95
2 additional pooled analyses, 96,97 and 1 retrospective study
(n = 5917)98 on the yield of alternative screening strategies in a
cohort of patients in a national survey were included (Figure 2).
Eighty-three studies12-62,64,66-74,77,79,81-83,85-92,95-98 were new for
this update, and 963,65,75,76,78,80,84,93,94 were carried forward
from the previous USPSTF review.

Benefits of Screening
Key Question 1a. Does screening for HCV infection in pregnant and
nonpregnant adolescents and adults without known abnormal liver
enzyme levels reduce HCV-related mortality and morbidity or affect
quality of life?
No study met inclusion criteria for this KQ.
Key Question 2. What is the effectiveness of different riskor prevalence-based methods for screening for HCV infection on
clinical outcomes?
No study met inclusion criteria for this KQ.
Key Question 3. What is the yield (number of new diagnoses
per tests performed) of 1-time vs repeat screening or alternative
screening strategies for HCV infection, and how does the screening yield vary in different risk groups?
A retrospective study (n = 5917) compared the yield of
risk-based HCV screening vs birth cohort screening in a cohort
of patients sampled from the National Health and Nutrition
Examination Survey. 9 8 It found that applying risk-based
guidelines perfectly would screen 24.7% of the US general
population and identify 82% of HCV cases, with a number
needed to screen to identify 1 HCV case of 14.6. Applying the birth
cohort strategy would screen 45% of the general population and
identify 76% of cases, with a number needed to screen of 28.7.
No study evaluated the yield of 1-time vs repeat screening, the
yield of alternative screening strategies in different risk groups, or
the yield of currently recommended screening vs expanded
screening strategies.

Harms of Screening
Key Question 4. What are the harms of screening for HCV infection (eg, anxiety and labeling)?
No study compared harms of HCV screening vs no screening.
Poor-quality evidence from the prior USPSTF review suggested
potential negative psychological and social effects of screening
but was uncontrolled and did not meet inclusion criteria for this
update.

Benefits of Treatment
Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?

US Preventive Services Task Force Clinical Review & Education

Adults
Quality of Life/Function | Ten open-label treatment studies
(n = 2404) reported quality-of-life and functional outcomes
before and after receipt of current DAA regimens (eTable 1 in the
Supplement). Seven studies were included in 2 pooled
analyses,95,96 and there were 3 additional studies (reported in 2
publications).12,99
At 12 weeks after treatment, 2 pooled analyses found
sofosbuvir/velpatasvir (4 trials) or sofosbuvir/ledispavir (3 trials)
associated with improvements in some measures of quality of
life or function compared with before treatment, though differences were small (eg, less than 3 points on the 36-Item Short
Form Health Survey physical and mental component summary
scales [range, 0-100 points] or 0.04 to 0.05 points on the
6-Dimensional Health State Form health utility scale), and not all
differences were statistically significant.95,96 Results were similar
in 2 studies of ombitasvir/paritaprevir/ritonavir/dasabuvir12 or
elbasvir/grazoprevir.99
Mortality | Thirty-one treatment studies (in 28 publications;
n = 3848) reported mortality at 12 to 36 weeks after completion of
DAA therapy but were not designed to assess this
outcome.14-19,24,25,27,28,30-32,36,37,39,41-44,46,48,49,51-55 Twenty-one
studies reported no deaths, and the remaining 10 studies reported
17 deaths (0.4% overall. Ten deaths occurred in 3 studies of persons reporting recent injection drug use or use of opioid substitution therapy.31,32,55
Other Clinical Outcomes | Three cohort studies (n = 58 892) evaluated other clinical outcomes (eTable 2 in the Supplement).67,68,83
Follow-up ranged from 1.1 to 7.4 years. One study found DAA therapy,
vs interferon-based therapy or antiviral therapy, was associated with
decreased risk of cardiovascular events, including acute myocardial infarction, congestive heart failure, and stroke (incidence rate
per 1000 person-years of follow-up, 16.3 [95% CI, 14.7 to 18.0] for
DAA therapy; 23.5 [95% CI, 21.8 to 25.3] for interferon-based therapy;
and 30.4 [95% CI, 29.2 to 31.7] for no therapy; P < .001 for antiviral
therapy vs no therapy).67 One study found DAA and interferonbased therapy associated with similar incidence of hepatocellular carcinoma that was lower than with no antiviral therapy (incidence rate
per 1000 person-years, 7.5 [95% CI, 6.5 to 8.6] and 7.9 [95% CI, 6.0
to 10.4] for antiviral therapy and 10.9 [95% CI, 9.92 to 11.97] for no
therapy; P value not reported).83 The third study found no difference between DAA therapy vs no antiviral therapy in risk of hepatocellular carcinoma (adjusted HR, 1.02 [95% CI, 0.40 to 2.61]); point
estimates for associations with all-cause mortality favored DAA
therapy, but the difference was not statistically significant (adjusted HR, 0.74 [95% CI, 0.43 to 1.28]).68
Adolescents

Three treatment studies of adolescents (n = 200) reported changes
of 2 to 13 points on Pediatric Quality of Life Inventory (scale, 0-100)
scores after treatment with DAA therapy compared with baseline;
effects were not always statistically significant (eTable 3 in the
Supplement).59,61,100 Treatment studies of DAA therapy in adolescents were not designed to evaluate mortality (no deaths in 3
studies)57,61,62 or long-term clinical outcomes.
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Some studies were included for multiple key questions (KQs).

Addressed in the full evidence report.

1 Article (1 study)
from current review
included for KQ3

b

0 Articles included
for KQ2

a

0 Articles included
for KQ1

136 Citations identified from prior review

5 Articles (5 studies)
included for KQ5b
1 From current
review
4 Carried over from
prior review

36 Articles (40 studies)
from current review
included for KQ6

94 Articles (97 studies) includeda
81 Articles (84 studies) from current review
13 Articles (13 studies) carried over from prior review

53 Articles (56 studies)
from current review
included for KQ7

53 Articles (56 studies)
from current review
included for KQ8

606 Articles excluded
123 Included in prior review but excluded from current review
10 Excluded population
43 Excluded intervention
4 Excluded outcome
1 Not a study (eg, letter, editorial, nonsystematic review,
no original data)
3 Inadequate duration
24 Poor quality
1 Insufficient statistical analyses
37 Outdated medication
483 New articles excluded
110 Excluded population
91 Excluded intervention
49 Excluded outcome
12 Excluded comparator
85 Excluded study design for KQ
63 Not a study (eg, letter, editorial, nonsystematic review,
no original data)
53 Systematic review used as a source document only
to identify individual studies
4 Excluded country
7 Poor quality
9 Insufficient statistical analyses

700 Full-text articles assessed for eligibility for any KQ

0 Articles included
for KQ4

30 Articles (30 studies)
included for KQ9
21 From current
review
9 Carried over
from prior
review

245 Citations identified through other sources (eg, prior reports,
reference lists of relevant articles, systematic reviews)

6470 Citations excluded based on review of title and abstract

7170 Citations screened after duplicates removed

7383 Citations identified through literature database searches

Figure 2. Literature Search Flow Diagram: Screening for Hepatitis C Virus Infection in Adolescents and Adults
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Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving an SVR in patients
with HCV infection?
Adults

Forty-nine studies (in 44 publications; n = 10 181) reported effects of
current DAA treatment regimens on SVR in patients with HCV
infection.12-55 SVR was measured 12 weeks after the completion of
therapy in all studies except for 1, which measured SVR at 14 weeks.
Sample sizes ranged from 20 to 706, mean age ranged from 45 to 68
years, and the proportion of women ranged from 18% to 64%; the
studies evaluated 7 different antiviral regimens (eTable 4 in theSupplement). One study was a randomized trial that compared a current DAA
regimen vs placebo,14 2 randomized trials (reported in 1 publication)
compared a current DAA regimen vs a regimen with telaprevir,12 and
2 randomized trials (reported in 1 publication) compared a current vs
older DAA regimen.15 The other treatment studies did not compare a
current DAA regimen vs placebo or an older regimen.
Thirteen studies were rated as good quality12-14,17,19,28,29,33,35,
36,46,51,54 and the remainder as fair quality (eTable 5 in the Supplement). Methodological limitations included unclear randomization or
enrollment methods. Loss to follow-up was low (range, 0%-3%).
All of the trials were industry-funded.
SVR Rates in Comparative Trials | Few studies compared DAA interventions with placebo or older interventions (eTable 5 in the Supplement). One randomized trial found sofosbuvir/velpatasvir associated with very high likelihood of SVR vs placebo in persons with mixedgenotype (1, 2, 4, 5, or 6) infection (99% vs 0%; relative risk [RR], 231.6
[95% CI, 14.6 to 3680]).14 Two randomized trials found ombitasvir/
paritaprevir/ritonavir/dasabuvir (with or without ribavirin) associated with increased likelihood of SVR vs telaprevir/pegylated interferon/ribavirin in treatment-naive persons with genotype 1 infection
(98% vs 80%; RR, 1.22 [95% CI, 1.08 to 1.37]) or persons previously
treated with interferon therapy (99% vs 66%; RR, 1.50 [95% CI, 1.22
to 1.85]).12 Two randomized trials found sofosbuvir/velpatasvir for 12
weeks associated with increased likelihood of SVR vs sofosbuvir/
ribavirin for 24 weeks for genotype 2 (99% vs 94%; RR, 1.06 [95%
CI, 1.01 to 1.11]) and for genotype 3 infection (noncirrhosis subgroup,
97% vs 87%; RR, 1.11 [95% CI, 1.05 to 1.18]).15
Pooled SVR Rates | For genotype 1 HCV infection, the most common genotype in the US, DAA therapy was associated with a pooled
SVR rate of 97.7% (95% CI, 96.6% to 98.4%; I2 = 82%) based on 32
studies (n = 6055) (Figure 3). Evidence for genotypes 2 through 6
was more limited, ranging from 75 to 742 participants per genotype (eTable 7 in the Supplement). The pooled SVR rates ranged from
95.5% to 98.9%; for other common US genotypes, the pooled SVR
was 98.9% (95% CI, 97.5% to 99.5%; I2 = 4%) for genotype 2 (5
studies, n = 526) (eFigure 1 in the Supplement), 95.5% (95% CI,
91.6% to 97.7%; I2 = 66%) for genotype 3 (6 studies, n = 742) (eFigure 2 in the Supplement), and 98.2% (95% CI, 94.7% to 99.4%;
I2 = 50%) for genotype 4 (10 studies, n = 485) (eFigure 3 in the
Supplement). Across genotypes, SVR estimates were consistent
when studies were stratified according to study quality, geographic setting, prior HCV treatment, inclusion of some patients with
cirrhosis at baseline, and use of ribavirin as recommended (eTable 7
in the Supplement).

US Preventive Services Task Force Clinical Review & Education

Adolescents

Seven studies (n = 348) evaluated the effects of DAA regimens on
SVR in adolescents (eTable 8 in the Supplement).56-62 Mean age
ranged from 12 to 15 years, and the proportion of female participants ranged from 35% to 66%. Three of the 7 studies were conducted in Egypt and focused on genotype 4 infection, 1 study enrolled patients with genotype 1, and 3 studies enrolled mixed
genotypes. Four studies evaluated DAA regimens approved by the
US Food and Drug Administration (FDA) for use in adolescents,57-59,61
and the others evaluated DAA regimens recommended for adults
but not FDA-approved for adolescents.56,60,62 Across all intervention studies of DAA in adolescents, the SVR rate ranged from 97%
to 100%.

Harms of Treatment
Key Question 8. What are the harms of currently recommended antiviral treatments?
Adults

Forty-nine treatment studies (in 44 publications; n = 10 181) of DAA
regimens without interferon reported the proportion of patients who
experienced adverse events at short-term follow-up (ie, while taking antiviral therapy through up to 12 weeks after completion of
therapy).12-55
Adverse Events in Comparative Trials | Four randomized trials (total
n = 2113) reported adverse events associated with current DAA regimens vs placebo (eTable 9 in the Supplement).13,14,16,17 DAA regimens were associated with slightly increased risk of any adverse
event (4 trials; RR, 1.12 [95% CI, 1.02 to 1.24]; I2 = 46%; absolute risk
difference [ARD], 8% [95% CI, 8% to 15%]) (eTable 9 in the Supplement). DAA therapy was also associated with increased risk of nausea (3 trials; RR, 1.42 [95% CI, 1.00 to 2.03]; I2 = 10%; ARD, 4% [95%
CI, −3% to 10%]); the association with increased risk of diarrhea was
not statistically significant (2 trials; RR, 1.53 [95% CI, 0.88 to 2.68];
I2 = 29%). There were no differences between DAA regimens vs placebo in risk of serious adverse events, withdrawal due to adverse
events, headache, or fatigue.
Two randomized trials (reported in 1 publication; n = 457) compared a DAA regimen (ombitasvir/paritaprevir/ritonavir/dasabuvir
with or without ribavirin) vs telaprevir/pegylated interferon/
ribavirin for genotype 1 infection (eTable 10 in the Supplement).12
DAA therapy was associated with decreased risk of serious adverse
events (RR, 0.08 [95% CI, 0.02 to 0.34]; I2 = 0%; ARD, −8% [95%
CI, −15% to −1%]) and withdrawal due to adverse events (RR, 0.06
[95% CI, 0.01 to 0.29]; I2 = 0%; ARD, −9% [95% CI, −14% to −3%])
vs the telaprevir regimen. DAA therapy was also associated with decreased risk of fatigue, headache, nausea, anemia, and rash (eTable 10
in the Supplement).
Pooled Adverse Event Rates for DAA Regimens | DAA therapy was frequently associated with experiencing any adverse event (44 trials,
n = 8045; 73.3% [95% CI, 68.0% to 78.1%]; I2 = 95%) (eFigure 4
in the Supplement), though serious adverse events (44 studies,
n = 8070; 1.9% [95% CI, 1.5% to 2.4%]; I2 = 33%) (eFigure 5 in the
Supplement) and withdrawal due to adverse events (44 studies,
n = 8060; 0.4% [95% CI, 0.3% to 0.6%]; I2 = 0%) (eFigure 6 in the
Supplement) were infrequent (eTable 11 in the Supplement). Pooled
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Figure 3. Direct-Acting Antiviral Regimens and Pooled Sustained Virologic Response Rates in People With Genotype 1 Hepatitis C Virus Infection
Source
Country
Age, y Women, %
Ledipasvir/sofosbuvir
Afdhal et al,35 2014
Multinational 52
41
Kowdley et al,35 2014
US
53
40
Lawitz et al,40 2014
US
48
38
Chuang et al,27 2016
Taiwan
55
58
Lim et al,42 2016
Korea
54
61
Wei et al,53 2018
China
47
50
Subtotal: I2 = 88.7%, P <.001
Simeprevir/sofosbuvir
Lawitz et al,39 2014
US
56
29
Kwo et al,37 2016
Canada and US 56
47
Pott-Junior et al,46 2019 Brazil
53
48
Subtotal: I2 = 0.0%, P = .50
Sofosbuvir/velpatasvir
Everson et al,28 2015
US
49
39
Feld et al,14 2015
Multinational 54
40
Wei et al,17 2019
Multinational 45
47
Subtotal: I2 = 26.6%, P = .26
Elbasvir/grazoprevir
Sulkowski et al,49 2015
Multinational 51
51
Zeuzem et al,54 2015
Multinational 52
46
Sperl et al,47 2016
Multinational 48
57
Ng et al,99 2018
Kumada et al,36 2017
Japan
61
62
Wei et al,53 2019
Multinational 48
56
Subtotal: I2 = 54.6%, P = .07
Sofosbuvir/daclatasvir
Sulkowski et al,48 2014
US
55
50
Pott-Junior et al,46 2019 Brazil
56
52
Subtotal: I2 = 45.3%, P = .18
Glecaprevir/pibrentasvir
Poordad et al,45 2017
US
58
18
Chayama et al,26 2018
Japan
64
64
Zeuzem et al,55 2018
Multinational 53
51
Subtotal: I2 = 77.9%, P = .01
Ombitasvir/paritaprevir/ritonavir/dasabuvir
Lalezari et al,38 2015
US
48
34
Grebely et al,32 2018
Multinational 48
23
Subtotal: I2 = 26.7%, P = .24
Ombitasvir/paritaprevir/ritonavir/dasabuvir (genotype 1a)
Feld et al,13 2014
Multinational 49
43
Ferenci et al,29 2014
Multinational 51
35
Kowdley et al,34 2014
Multinational 50
42
Dore et al,12 2016a
Multinational 46
39
Dore et al,12 2016b
Multinational 47
46
Subtotal: I2 = 77.2%, P = .002
Ombitasvir/paritaprevir/ritonavir/dasabuvir (genotype 1b)
Andreone et al,22 2014
Multinational 54
46
Feld et al,13 2014
Multinational 49
43
Ferenci et al,29 2014
Multinational 48
54
Kowdley et al,34 2014
Multinational 50
47
Kumada et al,16 2015
Japan
61
63
Lawitz et al,41 2015
Multinational 55
51
Dore et al,12 2016a
Multinational 46
54
Dore et al,12 2016b
Multinational 47
46
Subtotal: I2 = 68.5%, P = .002
Heterogeneity between groups: P = .005
Overall: I2 = 81.6%, P <.001

Fibrosis stage Treatment
(% cirrhosis) naive

Events/
total

0
0
0
≤20
≤20
≤20

Yes
Yes
Yes
Mixed
Yes
No

357/357
408/431
58/60
83/85
46/46
206/206

0
0
0

Mixed
Mixed
Mixed

61/64
0.953 (0.869-0.990)
150/155 0.968 (0.926-0.989)
0.933 (0.838-0.982)
56/60
0.957 (0.926-0.975)

0
0
≤20

Yes
Mixed
No

28/28
1.000 (0.877-1.000)
251/255 0.984 (0.960-0.996)
129/129 1.000 (0.972-1.000)
0.990 (0.954-0.998)

0
≤20
≤20

Yes
Yes
Mixed

122/129 0.946 (0.891-0.978)
273/288 0.948 (0.916-0.971)
122/123 0.992 (0.956-1.000)

0
≤20

Mixed
Yes

219/227 0.965 (0.932-0.985)
422/432 0.977 (0.958-0.989)
0.967 (0.950-0.978)

≤20
00

Yes
Mixed

80/82
65/65

00
Unclear/NR
00

No
Mixed
No

46/50
0.920 (0.808-0.978)
128/129 0.992 (0.958-1.000)
663/667 0.994 (0.985-0.998)
0.986 (0.941-0.997)

0
0

Mixed
Yes

37/38
73/80

0.974 (0.862-0.999)
0.913 (0.828-0.964)
0.932 (0.870-0.966)

Unclear/NR
0
0
0
0

Yes
Yes
Mixed
Mixed
Mixed

307/322
282/305
183/212
67/69
19/19

0.953 (0.924-0.974)
0.925 (0.889-0.952)
0.863 (0.809-0.906)
0.971 (0.899-0.996)
1.000 (0.824-1.000)
0.937 (0.890-0.965)

0
Unclear/NR
0
0
0
0
0
0

No
Yes
Yes
Mixed
Mixed
Mixed
Mixed
Mixed

176/179
148/151
416/419
113/113
204/215
76/82
164/167
81/82

0.983 (0.952-0.997)
0.980 (0.943-0.996)
0.993 (0.979-0.999)
1.000 (0.968-1.000)
0.949 (0.910-0.974)
0.927 (0.848-0.973)
0.982 (0.948-0.996)
0.988 (0.934-1.000)
0.982 (0.964-0.991)
0.977 (0.966-0.984)

Effect size (95% CI)
1.000 (0.990-1.000)
0.947 (0.921-0.966)
0.967 (0.885-0.996)
0.976 (0.918-0.997)
1.000 (0.923-1.000)
1.000 (0.982-1.000)
0.994 (0.952-0.999)

0.976 (0.915-0.997)
1.000 (0.945-1.000)
0.986 (0.947-0.997)

0

.25

.5

.75

1

Effect size (95% CI)

The area of each square represents each pooled estimate (subgroup or overall
analysis), and the width of each diamond represents the confidence interval for
the pooled estimate. The dashed line indicates the overall measure of effect.
SVR indicates sustained virologic response.
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a

Treatment-naive.

b

Treatment-experienced.
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rates for specific adverse events ranged from 2.4% (anemia) to 18.7%
(headache) (eTables 12 and 13 in the Supplement). There was some
variability by DAA regimen in estimates of adverse events; estimates were generally higher for ombitasvir/paritaprevir/ritonavir/
dasabuvir with ribavirin than without ribavirin (eTables 11-13 in the
Supplement). Adverse event estimates were generally similar when
studies were stratified according to baseline cirrhosis status and prior
antiviral therapy experience.
Adolescents

Seven treatment studies (n = 348) of DAA regimens in adolescents
reported harms, but methods for reporting and assessing harms were
generally not well described (eTable 14 in the Supplement).56-62
Rates of any adverse event were 27% in 1 study62 and ranged from
71% to 87% in 4 studies.57,59-61 There were no withdrawals due to
adverse events reported in 5 studies,57,59-62 and 1 study61 reported
1 serious adverse event (a grade 3 joint injury). Rates of other adverse events were highly variable. For example, 3% to 48% of study
participants reported headache. Stratification according to DAA regimen did not explain the observed variability.

SVR and Health Outcomes
Key Question 9. What is the association between experiencing SVR
following antiviral treatment and reduction in risk of HCV-related adverse health outcomes?
Thirty cohort studies reported associations between achieving
SVRafterantiviraltreatmentvsnoSVRandclinicaloutcomes(eTable15
in the Supplement).63-66,68-82,84-94 Sample sizes ranged from 131 to
50 886 (total n = 116 659), mean age ranged from 42 to 69 years, and
the proportion of women ranged from 1% to 56%. Seventeen studies were conducted in Japan (including some with overlapping
populations),63,64,71,73-75,78-81,84-86,89,90,92,93 4 in other Asian
countries,82,88,91,94 7 in the US (all except for 187 conducted in Veterans Affairs populations),65,66,69,70,72,77,87 and 2 in Europe.68,76 When
genotype was reported, genotype 1 was generally the most common
(36%-89%) and genotype 2 the second most common (6%-52%).
Mean follow-up ranged from 1.5 to 10 years in all studies except for 1
study that described follow-up of at least 1 year.88 Twenty-six studies evaluated interferon-based therapies. Three studies focused on
DAAs,66,68,77 1 study evaluated interferon-based treatments and
DAAs,77 and 1 study did not report what type of treatment was administered (likely primarily interferon-based therapies).72 All studies
were rated fair quality (eTable 16 in the Supplement).
SVR was associated with significantly decreased risk of all-cause
mortality (13 studies, n = 36 986; HR, 0.40 [95% CI, 0.28 to 0.56];
I2 = 52%) (Figure 4).63,65,66,68-70,75,76,80,84,87,93,94 Studies with longer duration of follow-up (>5 years) reported a stronger association
between SVR after antiviral therapy and reduced risk of all-cause mortality (pooled HR, 0.33 [95% CI, 0.24 to 0.46]) than those with shorter
follow-up (pooled HR, 0.64 [95% CI, 0.56 to 0.74]) (P = .003 for interaction). SVR was also associated with decreased risk of hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29 [95% CI, 0.23
to 0.38]; I2 = 19%) (Figure 4),63,64,68,70-74,77-79,81,82,84-86,89,90,92,94
liver-related mortality (4 studies, n = 5953; pooled HR, 0.11 [95% CI,
0.04 to 0.27]; I2 = 0%) (eFigure 7 in the Supplement),63,75,80,93 and
cirrhosis (4 cohorts reported in 3 studies, n = 16 735; pooled HR, 0.36
[95% CI, 0.33 to 0.40]; I2 = 0%) (eFigure 8 in the Supplement).69,72,91
There were no statistically significant interactions when studies were

US Preventive Services Task Force Clinical Review & Education

stratified according to how well they adjusted for key confounders,
duration of follow-up, country/setting, or the proportion of participants with cirrhosis at baseline (eTable 15 in the Supplement). Results were also similar when studies with potentially overlapping populations were excluded.

Discussion
The findings in this evidence report are summarized in the Table.
Since the prior USPSTF recommendation, there has been a major
shift in antiviral therapy to all-oral DAA regimens without interferon. New pooled evidence indicates that SVR rates with currently recommended all-oral DAA regimens are substantially higher
(>95%) than with interferon-based therapies evaluated in the prior
review (68%-78%).9 Although statistical heterogeneity was present in pooled estimates of SVR rates, findings were robust when
studies were stratified according to the DAA regimen evaluated,
study quality, prior treatment status, and cirrhosis status. Few randomized trials directly compared a current DAA regimen vs placebo or an older antiviral regimen, but those available also found DAA
therapy associated with greater effectiveness. DAA regimens were
associated with fewer harms than older interferon-containing therapies. Evidence on DAA therapies in adolescents was limited, but consistently reported high (97%-100%) SVR rates.
Direct evidence on the effects of antiviral therapy on clinical outcomes is limited. Although several randomized trials found interferon therapy associated with decreased risk of hepatocellular carcinoma compared with no antiviral therapy, they did not meet
inclusion criteria for this report because they focused on patients
with cirrhosis at baseline or used a nonstandard regimen.101-108 Studies of DAA therapies were not designed to assess effects on mortality or other long-term clinical outcomes. There were few cohort
studies of antiviral therapy vs no therapy, results were somewhat
inconsistent, and findings were susceptible to residual confounding. Given the limited direct evidence on the effects of antiviral
therapy on clinical outcomes, cohort studies of the association between SVR after antiviral therapy vs no SVR and clinical outcomes
may help to understand potential clinical effects of DAA therapy. As
in the prior USPSTF review, there was a consistent association between SVR after antiviral therapy and improved clinical outcomes,
including mortality and hepatocellular carcinoma.9
The findings in this evidence report regarding the benefits and
harms of current DAA regimens were consistent with a recent systematic review that also reported high (>95%) SVR rates in genotype 1 infection without cirrhosis, high SVR rates but more limited
evidence for other HCV genotypes, low rates of serious adverse
events and treatment discontinuation, and higher adverse event
rates with ribavirin.109 The results are also consistent with a systematic review that found insufficient evidence from clinical trials
to determine effects of DAA regimens on HCV-related mortality and
morbidity110; unlike that review, this one also evaluated the indirect chain of evidence linking DAA therapy with SVR, and SVR with
clinical outcomes. This review is consistent with prior reviews that
found a consistent association between an SVR after antiviral therapy
and reduced risk of mortality and hepatocellular carcinoma.111-113
Research is needed to better understand the association between use of current DAA therapy and clinical outcomes. Long-term
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Duration, y
5.4
8.2
5.7
5.2
7.4
3.8
5.3
9.9
10.0
5.0
7.5
1.5
2.8
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Country
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
Asia
US
US
Asia
US
Europe

Country
Asia
Asia
Asia
Asia
Asia
US
Europe
Asia
US
US
US
US
Europe

Restricted to F0-F1
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
NR/unclear
No
No
No

Restricted to F0-F1
No
No
No
No
No
No
No
No
No
No
No
Yes
No

Cirrhosis, %
0-10
0-10
>10
0-10
0-10
0-10
0-10
>10
>10
0-10
0-10
>10
0-10
0-10
NR/unclear
>10
NR/unclear
>10
>10
0-10

Cirrhosis, %
0-10
>10
>10
>10
>10
>10
>10
0-10
0-10
>10
>10
>10
0-10

Treatment
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
NR
Interferon
Mixed
DAA

Treatment
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
Interferon
DAA
DAA

% Genotype 1
NR
58
67
70
75
NR
50
46
60
73
70
72
73
60
67
70
55
51
77
67

% Genotype 1
NR
74
NR
46
60
72
36
73
61
68
70
85
67

SVR/no SVR
151/268
313/405
606/585
789/1568
175/419
426/358
155/340
715/342
140/360
139/264
686/1356
139/234
221/356
185/197
285/189
222/314
7577/8767
306/183
28 655/23 231
3286/146

SVR/no SVR
817/1613
116/239
738/1930
715/342
140/360
7434/9430
560/655
221/356
69/71
83/159
222/314
6371/599
3286/146

Hazard ratio (95% CI)
0.06 (0.01-0.48)
0.19 (0.06-0.58)
0.33 (0.12-0.96)
0.32 (0.14-0.70)
0.29 (0.07-1.28)
0.13 (0.06-0.27)
0.36 (0.04-0.83)
0.24 (0.11-0.52)
0.19 (0.08-0.45)
0.28 (0.08-0.96)
0.38 (0.18-0.83)
0.14 (0.04-0.52)
0.12 (0.03-0.41)
0.12 (0.01-0.94)
0.39 (0.32-0.48)
0.41 (0.18-0.96)
0.30 (0.23-0.38)
0.09 (0.02-0.40)
0.32 (0.28-0.37)
0.22 (0.03-1.76)
0.29 (0.23-0.38)

Hazard ratio (95% CI)
0.32 (0.12-0.86)
0.35 (0.09-1.36)
0.24 (0.08-0.68)
0.28 (0.08-1.02)
0.39 (0.16-0.93)
0.66 (0.57-0.76)
0.22 (0.09-0.58)
0.20 (0.08-0.54)
0.50 (0.12-2.10)
0.11 (0.03-0.47)
0.47 (0.26-0.85)
0.57 (0.33-0.99)
1.36 (0.15-12.35)
0.40 (0.28-0.56)

0.02

0.06 0.1

1

0.1

1

Hazard ratio (95% CI)

Favors SVR

4

Favors No SVR

4

Favors No SVR

Hazard ratio (95% CI)

Favors SVR

effect; overall estimates were from mixed-effects models. DAA indicates direct-acting antiviral; IFN, interferon;
NR, not reported; SVR, sustained virologic response.

Adjustment
Partial
Full
Full
Partial
Full
Partial
Unclear
Full
Full
Partial
Full
Full
Full
Partial
Partial
Full
Full
Full
Full
Full

Adjustment
Partial
Partial
Partial
Full
Full
Full
Full
Full
Full
Full
Full
Full
Full

The area of each square represents each pooled estimate (subgroup or overall analysis), and the width of each
diamond represents the confidence interval for the pooled estimate. Dashed lines indicate the overall measures of

5.2
7.4
3.0
7.5
8.2
9.9
4.1
4.8
7.5
5.2
2.6
6.1
2.8

Duration, y
4.0
3.1
5.4
4.3
4.8
5.6

SVR vs no SVR: hepatocellular carcinoma

Source
Imai et al,74 1999
Kasahara et al,79 1998
Ikeda et al,73 1999
Yoshida et al,92 1999
Tanaka et al,89 2000
Okanoue et al,85 2002
Izumi et al,78 2005
Yu et al,94 2006
Arase et al,63 2007
Kurokawa et al,81 2009
Asahina et al,64 2010
Tateyama et al,90 2011
Maruoka et al,84 2012
Osaki et al,86 2012
Dohmen et al,71 2013
Dieperink et al,70 2014
El-Serag et al,72 2014
Lee et al,82 2017
Ioannou et al,77 2018
Carrat et al,68 2019
Overall: I2 = 18.7%, P = .22

B

Source
Yoshida et al,93 2002
Imazeki et al,75 2003
Kasahara et al,80 2004
Yu et al,94 2006
Arase et al,63 2007
Backus et al,65 2011
Innes et al,76 2011
Maruoka et al,84 2012
Cozen et al,69 2013
Singal et al,87 2013
Dieperink et al,70 2014
Butt et al,66 2017
Carrat et al,68 2019
Overall: I2 = 52.1%, P = .02

A SVR vs no SVR: all-cause mortality

Figure 4. Association of Sustained Virologic Response With Clinical Outcomes

Clinical Review & Education US Preventive Services Task Force
USPSTF Report: Screening for Hepatitis C Virus Infection in Adolescents and Adults

jama.com

NA

NA

Summary of findings

jama.com

© 2020 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Portland State University User on 04/13/2020

Two pooled analyses of 3 and 4 studies each and data from 3 other
studies not included in pooled analyses found small, short-term
improvements in quality of life scale scores after DAA therapy
compared with before
In 31 DAA therapy studies reporting short-term (<1 y) mortality,
there were no deaths in 21 studies; mortality was low in the
remaining 10 studies (0.4% [17/3848] overall)
Two large observational studies found use of both DAA regimens
associated with lower rates of cardiovascular events and
hepatocellular cancer; these associations were not found in a third,
smaller observational study with shorter duration of follow-up

3 Treatment studies in 5
publications (n = 230)

There were no deaths in 3 studies of DAA regimens reporting
short-term mortality
Sofosbuvir with ledipasvir or ribavirin and glecaprevir with
pibrentasvir were associated with small improvements in Pediatric
Quality of Life Inventory scores compared with baseline

KQ6: Effect of treatment on health outcomes—adolescents

Prior review: NA (outdated
regimens)
New evidence: 37 studies (34
treatment studies [n = 4434],
2 pooled analyses [n = 2706],
3 observational studies
[n = 58 892])

Reasonably
consistent and
precise

NA

NA

Consistency
and precision

Fair

Poor

Fair

NA

NA

Overall
quality

Fair
Could not be
determined
(for quality of
life); imprecise

Consistent;
imprecise

Low
Poor-quality evidence from the prior review suggested potential
negative psychological and social effects of screening; these studies consistency
and precision
did not meet inclusion criteria for this update
No new studies on harms of screening meeting inclusion criteria
were identified

The prior review included 5 studies that found risk-based screening
associated with sensitivities of >90% and NNSs <20 to identify 1
case of HCV infection
One new study found that perfect application of risk-based
guidelines would identify 82% of HCV cases with an NNS of 14.6 to
identify 1 case of HCV infection, while applying a birth cohort
strategy would result in 76% of cases identified with an NNS of
28.7

KQ6: Effect of treatment on health outcomes—adults

Prior review: 5 studies (1
cross-sectional study [n = 34],
3 intervention series studies
[n = 220], 1 controlled trial
[n = 34])
New evidence: no new studies

KQ4: Harms of screening

Prior review: 5 studies (4
cross-sectional studies
[n = 7615] and 1 case-control
study [n = 429])
New evidence: 1 retrospective
study evaluating screening
yield (n = 5917)

KQ3: Screening strategies and yield

No studies

KQ2: Screening strategies

No studies

KQ1: Benefits of screening

Study design

Table. Summary of Evidence

Studies were not designed to assess
long-term health outcomes
The only evidence on quality of life
outcomes is based on a post hoc
analysis of study data

Studies reporting quality of life and
function were not randomized, used
an open-label design, and did not
have a non-DAA comparison group
Studies provided short-term
follow-up and were not designed to
assess health outcomes
Event rates for mortality were low
across studies, and other health
outcomes were not widely reported
Evidence on long-term clinical
outcomes was limited to 3
observational studies

Small sample sizes, no unscreened
comparison group, reliance on
retrospective recall, poorly defined
outcomes

Studies were retrospective, and in
some studies significant proportions
of patients were not tested
No studies of the yield of 1-time vs
repeat screening, alternative
screening strategies in different risk
groups, or the yield of currently
recommended screening vs expanded
screening strategies

NA

NA

Body of evidence limitations

Low

Low

Low

Low

NA

NA

EPC assessment
of strength of
evidence for KQ

(continued)

One study evaluated a DAA regimen not
FDA-approved for use in adolescents

Studies did not enroll a high proportion
of patients with cirrhosis at baseline
and evaluated current DAA regimens
Evidence on effects on hepatocellular
cancer and cardiovascular events was
primarily derived from a VA database
that included few female individuals
(3%-4%)

Studies were conducted in the era of
interferon-based treatments

Most studies conducted in
high-prevalence settings
One study assumed perfect application
of risk-based screening, which has not
been attainable

NA

NA

Applicability
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Summary of findings

DAA vs placebo (1 RCT): SVR, 99% vs 0%; RR, 231.6 (95% CI,
14.6-3680)
DAA vs telaprevir (2 RCTs): SVR, 98% vs 80%; RR, 1.22 (95% CI,
1.09-1.37) and 99% vs 66%; RR, 1.50 (95% CI, 1.22-1.85)
In 49 treatment studies, SVR rates with DAA therapies ranged from
95% to 100% across genotypes; estimates were consistent in
subgroup analyses based on study quality, geographic setting,
fibrosis status, prior treatment experience, and other factors;
results were also similar in trials that stratified patients according
to age, sex, race or ethnicity, or treatment experience

In 7 treatment studies, the SVR rate ranged from 97% to 100%
Rates were similar when stratified according to DAA treatment
regimen, genotype, and treatment history
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Pooled adverse event rates, DAA vs placebo:
Any adverse event (4 trials): RR, 1.12 (95% CI, 1.02-1.24);
I2 = 46%
Serious adverse events (4 trials): RR, 1.90 (95% CI, 0.73-4.95),
I2 = 0%
Withdrawal due to adverse events (4 trials): RR, 0.47 (95% CI,
0.14-1.58); I2 = 14%
Headache (4 trials): RR, 1.12 (95% CI, 0.91-1.37); I2 = 0%
Nausea (3 trials): RR, 1.42 (95% CI, 1.00-2.03); I2 = 10%
Diarrhea (2 trials): RR, 1.53 (95% CI, 0.88-2.68); I2 = 29%
Fatigue (3 trials): RR, 1.05 (95% CI, 0.78-1.40); I2 = 32%
Anemia (1 trial): RR, 2.21 (95% CI, 0.11-46)

2 RCTs (n = 459)

Pooled adverse event rates, DAA vs other antiviral treatment:
Any adverse event (2 trials): RR, 0.65 (95% CI, 0.50-0.84);
I2 = 87%
Serious adverse events (2 trials): RR, 0.08 (95% CI, 0.02-0.34);
I2 = 0%
Headache (2 trials): RR, 0.78 (95% CI, 0.58-1.04); I2 = 0%
Withdrawal due to adverse events (2 trials): RR, 0.06 (95% CI,
0.01-0.29); I2 = 0%
Fatigue (2 trials): RR, 0.37 (95% CI, 0.21-0.63); I2 = 32%
Headache (2 trials): RR, 0.70 (95% CI, 0.52-0.95); I2 = 0%
Nausea (2 trials): RR, 0.31 (95% CI, 0.16-0.59); I2 = 65%
Anemia (2 trials): RR, 0.09 (95% CI, 0.04-0.23); I2 = 41%
Rash (2 trials): RR, 0.19 (95% CI, 0.06-0.58); I2 = 48%

KQ8: Harms of treatment—adults: DAA vs other antiviral treatment

4 Randomized trials
(n = 2113)

KQ8: Harms of treatment—adults: DAA vs placebo

Prior review: NA
New evidence: 7
nonrandomized treatment
studies (n = 348)

KQ7: Effect of treatment on SVR—adolescents

Prior review: NA (outdated
regimens)
New evidence: 49 studies (8
RCTs and 41 nonrandomized
treatment studies;
n = 10 181)

KQ7: Effect of treatment on SVR—adults

Study design

Table. Summary of Evidence (continued)

Consistent;
precise

Consistent;
precise

Consistent;
imprecise

Consistent;
precise

Consistency
and precision

Fair

Fair

Fair

Good

Overall
quality

Few trials compared a DAA regimen
with an older antiviral regimen
Reporting of methods used to assess
and define was suboptimal
Trials did not report long-term
follow-up

Few trials compared a DAA regimen
with placebo
Reporting of methods used to assess
and define was suboptimal
Trials did not report long-term
follow-up

Evidence in adolescents with
genotype 2 and 4 infection was very
limited (n = 20)
Four studies were industry-funded

All studies were industry-funded
Most DAA studies did not include a
non-DAA comparison group
Evidence was most robust for
genotype 1 and more limited for
genotypes 2 through 6

Body of evidence limitations

Moderate

Moderate

Fair

High

EPC assessment
of strength of
evidence for KQ

See KQ7

See KQ7

(continued)

Three studies evaluated DAA regimens
not FDA-approved for use in
adolescents
Four studies were multinational
(primarily US and Europe) and 3 were
conducted in Egypt

SVR rates based on currently
recommended DAA regimens
Trials did not enroll a high proportion of
patients with cirrhosis at baseline
Most studies enrolled predominantly
white participants
Persons with current or recent drug use
excluded from most trials
Most trials were conducted in the US or
Europe or were multinational

Applicability
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Summary of findings

Pooled adverse events rates for currently recommended DAA
regimens:
Any adverse event (44 studies): 73.3% (95% CI, 68.0%-78.1%);
I2 = 95%
Serious adverse events (44 studies): 1.9% (95% CI, 1.5%-2.4%);
I2 = 33%
Withdrawal due to adverse events (44 studies): 0.4% (95% CI,
0.3%-0.6%); I2 = 0%
Anemia (13 studies): 2.4% (95% CI, 0.9%-6.3%); I2 = 85%
Fatigue (37 studies): 18.4% (95% CI, 15.6%-21.7%); I2 = 90%
Headache (42 studies): 18.7% (95% CI, 15.6%-22.2%); I2 = 90%
Insomnia (18 studies): 8.1% (95% CI, 6.7%-9.9%); I2 = 58%
Nausea (36 studies): 11.1% (95% CI, 9.1%-13.5%); I2 = 82%
Diarrhea (19 studies): 8.7% (95% CI, 7.0%-10.8%); I2 = 69%
Vomiting (6 studies): 5.8% (95% CI, 3.4%-9.7%); I2 = 43%
Rash (17 studies): 5.4% (95% CI, 4.1% to 7.1%); I2 = 70%
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Pooled estimates for health outcomes for SVR vs no SVR, in studies
in which <25% of the population had cirrhosis at baseline:
All-cause mortality (13 studies, 5 new): HR, 0.40 (95% CI,
0.28-0.56); I2 = 52%
Liver mortality (4 studies, 0 new): HR, 0.11 (95% CI, 0.04-0.27);
I2 = 0%
Cirrhosis (4 cohorts reported in 3 studies, all new): HR, 0.36 (95%
CI, 0.33-0.40); I2 = 0%
Hepatocellular carcinoma (20 studies, 16 new): HR, 0.29 (95% CI,
0.23-0.38); I2 = 19%
Estimates were consistent in analyses stratified according to
duration of follow-up, geographic setting, and level of statistical
adjustment for potential confounders
Consistent,
precise

Abbreviations: DAA, direct-acting antiviral; EPC, Evidence-based Practice Center; FDA, US Food and Drug
Administration; HCV, hepatitis C virus; HR, hazard ratio; KQ, key question; NA, not applicable;

Prior review: 19 cohort studies
(n = 30 692)
New evidence: 30 studies
(n = 116 659 [n = 26 191
from cohort studies included
in the prior report + n =
90 468 from new studies])

Consistent;
precise

Consistency
and precision

Inconsistent;
Five studies reported no withdrawals due to adverse events
imprecise
There was 1 serious adverse event (grade 3 joint injury) in 1 study
The rate of any adverse event was 27% in 1 study and 71%-87% in 4
studies
Specific adverse event rates:
Headache (7 studies): 3%-48%
Fatigue (7 studies): 5%-53%
Gastrointestinal adverse events (5 studies): 3%-28%
Insomnia (1 study): 23%

KQ9: Association between SVR and health outcomes

Prior review: NA
New evidence: 7 treatment
studies (n = 348)

KQ8: Harms of treatment—adolescents

Prior review: NA (outdated
regimens)
New evidence: 49 treatment
studies (n = 10 181)

KQ8: Harms of treatment—adults: overall

Study design

Table. Summary of Evidence (continued)

Studies are observational and
susceptible to confounding
Some studies appeared to evaluate
overlapping patient populations
About half (13) of the studies did not
address 4 prespecified potential
confounders in analyses (age, sex,
fibrosis stage, and genotype)

Studies did not have a non-DAA
comparison group
There was high variability in adverse
event rates, with no clear trends
when results were stratified
according to regimen
Reporting of methods used to assess
harms was suboptimal and long-term
follow-up (>48 wk) was not reported

Estimates were without a non-DAA
comparison group
Reporting of methods used to assess
and define was suboptimal
Studies did not report long-term
follow-up

Body of evidence limitations

Fair

Fair

Moderate

EPC assessment
of strength of
evidence for KQ

Most studies evaluated SVR after
interferon-based therapy; evidence on
SVR after DAA therapy was limited to 2
studies, one of which reported
imprecise estimates.
Studies did not enroll a high proportion
of patients with cirrhosis at baseline
Patients primarily received
interferon-containing therapy
Six of 7 US studies conducted in VA
populations
More than one-half of studies
conducted in Asia, but results similar
in US/Europe studies

See KQ6—adolescents

See KQ7

Applicability

NNS, number needed to screen; RCT, randomized clinical trial; RR, relative risk; SVR, sustained virologic response;
VA, Veterans Affairs.

Fair

Fair

Fair

Overall
quality
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randomized trials of treatment vs no treatment would be ethically
challenging and difficult to carry out. Alternatively, large cohort studies that measure important confounders could be highly informative. Trials and cohort studies that measure effects on quality of life,
function, and extrahepatic effects of HCV infection would also be
helpful for understanding effects of DAA regimens on these shorterterm clinical outcomes. Studies on the association between SVR after DAA therapy and clinical outcomes would help to verify the link
between SVR and clinical outcomes with current DAA therapies. Additional studies would be helpful for confirming the effectiveness
of DAA regimens in adolescents, including long-term outcomes.114
Well-designed prospective studies are needed to understand the effects of different HCV screening strategies, including repeat screening, on diagnostic yield.

Limitations
This review has several limitations. First, because there were few
randomized trials of current DAA regimens, nonrandomized treatment studies were included, among which were studies without a
non-DAA therapy comparison group. Causality cannot be concluded from such studies. Nonetheless, such studies were considered highly informative for SVR, an objective measure with rates
without treatment close to zero. However, more subjective outcomes such as quality of life, function, and adverse events are
more difficult to interpret in the absence of randomization or a
comparison group. Second, no study of DAA therapy was conducted in screen-detected patients, and few studies reported
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presence or severity of baseline symptoms. Therefore, to evaluate
effectiveness of DAA therapies in populations likely to be identified by screening, this report selected studies based on proxy factors, specifically a low prevalence of cirrhosis and prior DAA experience. Research studies of DAA therapy could overestimate SVR
rates compared with typical clinical practice. However, observational studies reported SVR rates of 90%, only modestly lower
than observed in the trials.115,116
Third, some studies of DAA therapy in adolescents evaluated
regimens approved for adults but not children. Fourth, evidence on
potential long-term harms of DAA therapy exposure was limited.
However, limited evidence indicates no increased risk of hepatocellular carcinoma with DAA therapy compared with interferonbased therapy through around 3 years of follow-up.68
Fifth, non–English-language articles were excluded. Sixth, formal assessment for small sample effects (a potential marker of publication bias) using graphical or statistical methods was not performed because of the small number of randomized trials.

Conclusions
Direct evidence on the effects of HCV screening on clinical outcomes remains unavailable, but all-oral DAA regimens were associated with SVR rates greater than 95% and few short-term harms relative to older antiviral therapies. An SVR after antiviral therapy was
associated with improved clinical outcomes compared with no SVR.
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